Knowledge PORTALS System (KPS) @LPBI
Knowledge PORTALS System (KPS) @LPBI is an initiative launched in September 2020 to manage the content creation @LPBI by our Final Improvement Team (FIT) members during the Transition Period that started on March 14, 2020 with the Launch of the Coronavirus Portal to cover eight aspects of the SARS-CoV-2 Pandemic @LPBI and which will end when CDC will announce that this Pandemic is over.
KPS is an infrastructure initiative designed to facilitate valuation for the following Intellectual Property Asset Classes:
| Asset Class IV |
Platforms
1.0 LPBI composition of methods and workflows for the content creation of scientific curations |
Valuation ~~~ $1.5MM |
|
Platforms: Five PORTALS & New Website 2.0 LPBI |
$5MM | |
| Asset Class VI |
Team of Experts: Human Capital component | _____________
~$3MM (1) BIOs Final Improvement Team (FIT) (2) Activities till 3/14/2020 (3) Activities during the Transition Period (4) Activities post Transition Period |
1.0 & 2.0 LPBI Group’s Team
- Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
- Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
- Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
- Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications
- Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
INACTIVE 12/31/2021
INACTIVE 12/31/2022
INACTIVE 12/31/2022
Joel Shertok, PhD – Affiliation with LPBI Group: 12/22/2019 – 5/4/2021
Justin D. Pearlman – External Scientific Relations: starting 5/12/2021
SCIENCE – Domains of Expertise
Responsibilities @LPBI:
(1) Curator initiated new content creation
(2) Updates to own published articles in the Journal
(3) Commissions by the Editor-in-Chief – One curation per WEEK
(4) Client facing engagement with External relations
(5) Advice for the Founder
Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6
https://pharmaceuticalintelligence.com/vision/
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector –THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery
TNS #6: e-Books Translations into Japanese, Spanish, Russian
Roles @ PharmaceuticalIntelligence.com
- Scientific Counsel: Life Sciences
- Advisor to the Founder
(1) TNS #1: https://www.wolfram.com/featureset/machine-learning/
1.1 LPBI LEAD on Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
1.2 LPBI LEAD on Application on the ingress TEXT from: Cancer Volume 1 & 2 and Genomics Volume 1 & 2
1.3 LPBI LEAD on Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
- The Wolfram Solution for Biological Sciences
- The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations
(2) TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: Blockchain vendor – lined them up and are willing to build the Front End
(3) Co-Editor LPBI Group’s BioMed Book #17 – COMPLETE Editorials by 12/10/2020
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS mean Knowledge VALUE
- Phase 1: Proof of Concept for 16 articles on Cardiovascular Diseases viewed >2,000
- Phase 2: Scale up to SIX volumes on Cardiovascular Diseases
https://lnkd.in/e6WkMgF
- Phase 3: Scale up to all articles in all CVD categories of Research
(1) TNS #1: https://www.wolfram.com/featureset/machine-learning/
1.1 LPBI LEAD on Comparison of NLP results obtained for Microsoft AZURE and EXPERIMENT with Text Analysis The Wolfram Language
1.2 LPBI LEAD on Application on the ingress TEXT from: Cancer Volume 1 & 2 and Genomics Volume 1 & 2
1.3 LPBI LEAD on Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
- The Wolfram Solution for Biological Sciences
- The Wolfram Data Drop is an open service that makes it easy to accumulate data of any kind, from anywhere—setting it up for immediate computation, visualization, analysis, querying, or other operations
(2) Commissions by the Editor-in-Chief – One Curation per WEEK
(3) TNS #5: Joint venture with Dr. Nir for Drug Discovery
(1) Curator initiated new content creation
(2) Updates to own published articles in the Journal
(3) Commissions by the Editor-in-Chief – One Curation per WEEK
(4) Co-Editor LPBI Group’s BioMed Book #17 – COMPLETE Editorials by 12/10/2020
(5) When LPBI works on TNS #1: Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
(5) Involvement with OWN created Content undergoing Text Analysis in TNS #1: Phase 3: Scaling up – Insights Interpretation stage
Founder & Director
- 1.0 LPBI Group, 4/2012 – 12/2020
- 2.0 LPBI Group, 1/2021 – 12/2025
Roles on 1.0 LPBI Group’s: (1) Transfer of IP Ownership and (2) Teams Exit
- Sourcing IB(s) and or Acquirer(s)
- Shepard Exit Transaction completion
- Transition under new ownership of LPBI IP portfolio
Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6
Author: 2020 VISION
- 2.0 LPBI Group, 1/2021 – 12/2025
https://pharmaceuticalintelligence.com/vision/
TNS #1: SEE https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector –THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA – Provide input in the selection of Interviewees
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery
TNS #6: e-Books Translations into Japanese, Spanish, Russian
BUSINESS & SCIENCE – Domains of Expertise
Science: AI in healthcare, AI in medical diagnosis, BioIT Bioinformatics, Biomarkers and medical diagnostics, Glycobiology, Cancer and current Therapeutics, Microbiome, Clinical diagnostics, Diagnostic immunology
Business:
- Biotech venture creation
- Joint Venture 2.0 LPBI Group (30%) with ABI-Lab (70%)
Business Development responsibilities @LPBI: Biotech in Israel, in Switzerland and in other countries in Europe
Plan for Business Development Activity at 1.0 LPBI 4Q 2020
-
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
Phase 1: Natural Language Processing(NLP) – 12 months FREE Microsoft AZURE for Health
- Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed byLPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery
- Inputs for Proof of Concept are the following three:
(1) Top 12 articles by views (all domains)
(2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1
(3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1
Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/
TNS #1: See above
TNS #2: EXEMPT due to conflict of interests
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery
TNS #6: e-Books Translations into Japanese, Spanish, Russian
Plan for Business Development Activity at 2.0 LPBI 1Q 2021
- PENDING
Science: Primary qualitative data collection: Interviewing techniques for content creation: e-Voices of Patients and Podcasts with scientific leaders, Customer Surveys design and collateral marketing communication content production
Business: Global communications consultant in pharmaceuticals/health care and biotechnology
Business Development responsibilities @LPBI: Monthly Newsletter and e-Voices Podcasts, emergence of an Audio & Video Library
2020 RESULTS
Plan for Business Development Activity at 1.0 LPBI 4Q 2020
- One newsletter, two podcasts, collaboration on web site design, regular article posting on LPBI web site
Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/
TNS #1: Not Applicable
TNS #2: Development of LPBI’s Narrowcasting messages for Blockchain Partner’s clients
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA – See 2020-2021 RESULTS
Development Plan for e-VOICES Podcasting, 2019 – 2021*
https://pharmaceuticalintelligence.com/audio-podcasts/
Podcast Interviewer INTERVIEWEE(S) Subject Date Audio/Video/ Narrator
Gail S. Thornton Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari 3D BioPrinting in Medicine 5/2019 Audio Gail S. Thornton Prof. Feldman Evolution Biology and Population Genetics 3/17/2020 Audio Gail S. Thornton Dr. Larry H. Bernstein, MD, FCAP Life Memoirs in Clinical Pathology Told 8/2020 Audio Narrator: Dr. S.J. Williams
Gail S. Thornton Dr. Justin D. Pearlman, MD, PhD Cardiac Imaging – Evolution of Diagnostic Methods 4Q 2020 Audio Gail S. Thornton Dr. Raphael Nir From Big Pharma to Biotech Entrepreneurship 2021 Audio Gail S. Thornton Dr. Meg Baker GlycoBiology in Practice 2021 Audio Gail S. Thornton Dr. Ofer Markman Memories of Procognia
2021 Audio *Dr. Williams and Aviva – will have their Podcasts in 2021.
TNS #4: Conversion – Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Not Applicable
TNS #6: e-Books Translations into Japanese, Spanish, Russian
Plan for Business Development Activity at 2.0 LPBI 1Q 2021
- One newsletter, two podcasts, continued refinement of web site design, regular article posting on LPBI web site
BUSINESS – Domains of Expertise
Verticals: (1) Chemical Industry (2) Financials & Insurance: Health Care (3) Biotech (4) Private Equity
Business Development responsibilities @LPBI:
(1) All Documentation Artifacts expected by External Relations
(2) Client facing engagement with External relations: Information Syndication
(3) Development of a Bot-based Global Prospecting System for LPBI
3.1 applications on ALA’s 7,200
3.2 applications on JTS’s 1st degree connections on LinkedIn
(4) LPBI’s LEAD all efforts with IB
(5) LPBI’s LEAD for all Partnerships:
5.1 LPBI J-V (30%) with ABI-Lab (70%)
5.2 Blockchain vendor
5.3 Agreements with Wolfram Machine Learning Approach https://www.wolfram.com/featureset/machine-learning/
Plan for Business Development Activity at 1.0 LPBI 4Q 2020
- 1,4,5, ABOVE
Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/
- 2,3,5, ABOVE
TNS #1: See 5.3, above – TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
TNS #2: See 5.2, above, Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: See 5.1, above Joint venture with Dr. Nir for Drug Discovery:
TNS #6: e-Books Translations into Japanese, Spanish, Russian
Plan for Business Development Activity at 2.0 LPBI 1Q 2021
- See 5.1, 5.2, 5.3, above
PROCESS of EMBEDDING A VIDEO on A PAGE on our Knowledge PORTALS System
[same for ANY PAGE on the website]
- You click on the VIDEO link
- You select a video you wish to embed
- You click on share – click on option <<EMBED>>> copy the link provided for embedding
- You go to our DASHBOARD
- You click all pages
- You type in name of the PAGE you manage on the Portal
- You find the Page and click EDIT
- You type the date
- You PASTE the embed link and the URL on Youtube
- You UPDATE
- You go to View Page
- You WATCH the VIDEO on our website
This page has the following sub pages.
- Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
- Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
- Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
- Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
- Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
- Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases and Co-Editor, Series D, Volume 4: Human Reproduction System
- Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
- Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
- Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22